Dapsone in dermatology and beyond

Archives of Dermatological Research

Volumn 306, Issue 2, 2014, Pages 103-124

  Wozel, Gottfried ^a   Blasum, Christian ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Department of Dermatology ^*  (Germany)

Author keywords

Adverse effects; Antiinflammatory mechanisms of action; Dapsone; Non dermatological disorders; Therapeutic strategies; Use in dermatology

Indexed keywords

ALPHA 1 ANTITRYPSIN; DAPSONE; EOSINOPHIL PEROXIDASE; INTERLEUKIN 8; LEUKOTRIENE B4; MYELOPEROXIDASE; PHOSPHOLIPID; PROSTAGLANDIN; PROTEINASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANTIMICROBIAL ACTIVITY; BLOOD TOXICITY; CAENORHABDITIS ELEGANS; CEREBROVASCULAR ACCIDENT; CHEMISTRY; CHEMOTAXIS; COMPLEMENT SYSTEM; DERMATOLOGY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EFFECTOR CELL; FIBRINOLYSIS; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HALOGENATION; HUMAN; LIFESPAN; LYMPHOCYTE FUNCTION; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PHOSPHOLIPID METABOLISM; PHOTOSENSITIVITY; PREGNANCY; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; TUMOR GROWTH;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DAPSONE; DERMATOLOGY; DISEASE MODELS, ANIMAL; EOSINOPHILS; HUMANS; NEUTROPHILS; SKIN DISEASES;

EID: 84896700466     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-013-1409-7     Document Type: Review

References (181)

1. Abe M, Shimizu A, Yokoyama Y, Takeuchi Y, Ishikawa O (2008) A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus. Clin Exp Dermatol 33:759-763
2. Ahmad RA, Rogers HJ (1980) Pharmacokinetics and protein binding interactions of dapsone and pyrimethamine. Br J Clin Pharmacol 10:519-524
3. Al-Said MS, Ghorab MM, Nissan YM (2012) Dapson heterocytic chemistry, part VIII: synthesis, molecular docking and anticancer activity of some novel sulfonylbiscompounds carrying biologically active 1,3-dihydropyridine, chromene and chromenopyridine moieties. Chem Cent J 6:64
4. Altagracia M, Monroy-Noyola A, Osorio-Rico L, Kravzov J, Varado-Calvillo R, Manjarrez-Marmolejo J, Rios C (1994) Dapsone attenuates kainic acid-induced seizures in rats. Neurosci Lett 176:52-54
5. Anderson R, Gatner EM, van Rensburg CE, Grabow G, Imkamp FM, Kok SK, van Rensburg AJ (1981) In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Anitmicrob Agents Chemother 19:495-503
6. Anderson R (1985) Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E2 by human polymorphonuclear leukocytes in vitro. Antimicrob Agents Chemother 27:257-362
7. Ashurst JV, Wasson MN, Hauger W, Fritz WT (2010) Pathophysiologic mechanisms, diagnosis, and management of dapsone-induced methemoglobinemia. J Am Osteopath Assoc 110:16-20
8. Barranco VP (1974) Inhibition of lysosomal enzymes by dapsone. Arch Dermatol 110:563-566
9. Beiguelman B, Pisam RC (1974) Effect of DDS on phytohemagglutinin-induced lymphocyte transformation. Int J Lepr Other Mycobact Dis 42:412-415
10. Berlow BA, Liebhaber MI, Dyer Z, Spiegel TM (1991) The effect of dapsone in steroid-dependent asthma. J Allergy Clin Immunol 87:710-715
11. Bernstein JE, Lorincz AL (1981) Sulfonamides and sulfones in dermatologic therapy. Int J Dermatol 20:81-88
12. Bissinger EM, Heinke R, Spannhoff A, Eberlin A, Metzger E, Cura V, Hassenboehler P, Cavarelli J, Schüle R, Bedford MT, Sippl W, Jung M (2011) Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg Med Chem 29:3717-3731
13. Blasum C (1998) Untersuchung zur Beinflussung der Interleukin-8-Spiegel in Lipopolysaccharid-stimulierten Vollblut gesunder Probanden durch in der Dermatologie angewandte antiinflammatorische Pharmaka mit antioxidativer Potenz. (Thesis). Technical University, University Hospital, Department of Dermatology, Dresden
14. Boehm I, Bauer R, Bieber T (1999) Urticaria treated with dapsone. Allergy 54:765-766
15. Bonney RJ, Wightman PD, Dahlgren ME, Sadowski SJ, Davies P, Jensen N, Lanza T, Humes JL (1983) Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis. Biochem Pharmacol 32:361-366
16. Booth SA, Moody CE, Dahl MV, Herron MJ, Nelson RD (1992) Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 98:135-140
17. Bordin L, Fiore C, Zen F, Coleman MD, Ragazzi E, Clari G (2010) Dapsone hydroxylamine induces premature removal of human erythrocytes by membrane reorganization and antibody binding. Br J Pharmacol 161:1186-1199
18. Boyer H, Nitti F, Tréfouel J (1937) Note preliminaire sur l'action de la paradiacetyl-aminodiphenyl sulfone (1399F) dans la blennorrhagic. Bul Soc Fr Dermatol Syphiligr 44:1889
19. Bozeman PM, Learn DB, Thomas EL (1992) Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 44:553-563
20. Branski D, Kerem E, Gross-Kieselstein E, Hurvitz H, Litt R, Abrahamov A (1986) Bloody diarrhea - a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr 5:316-317
21. Bundino S, Zina AM, Ubertalli S (1982) Infantile acropustulosis. Dermatologica 165:615-619
22. Buttle GAH, Stephenson D, Smith T, Dewing T, Foster GE (1937) The treatment of streptococcal infections in mice with 4: 2′diaminodiphenylsulfone. Lancet 229:1331-1334
23. Capstick RB, Lewis DA (1977) Aspects of the biochemistry and toxicology of dapsone and azapropazone. Drugs Exp Clin Res 2:79-87
24. Cassano N, D'Argento V, Filotico R, Vena GA (2005) Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venereol 85:254-255
25. Chen XY, Buschmann H, Bolm C (2012) Sulfoximine- and sulfilimine-based DAPSON analogs: syntheses and bioactivities. Synlett 23:2808-2810
26. Cho SC, Park MC, Keam B, Choi JM, Cho Y, Hyun S, Park SC, Lee J (2010) DDS,4,4′-diaminodiphenylsulfone, extends organismic lifespan. Proc Natl Acad Sci USA 107:19326-19331
27. Cho SC, Rhim JH, Son YH, Lee SJ, Park SC (2010) Suppression of ROS generation by 4,4-diaminodiphenylsulfone in non-phagocytic human diploid fibroblasts. Exp Mol Med 42:223-232
28. Cho SC, Rhim JH, Choi HR, Son YH, Lee SJ, Song KY, Park SC (2011) Protective effect of 4,4′-diaminodiphenylsulfone against paraquat-induced mouse lung injury. Exp Mol Med 43:525-537
29. Christoph H (1991) Experimentelle In-vivo-Untersuchungen von potentiellen topischen Antipsoriatika bzw. Antiphlogistika im Arachidonsäure- induzierten Mäuseohrschwellungstest (AA-Mest) (Thesis). Technical University, University Hospital, Department of Dermatology, Dresden
30. Cohen PR (2009) Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol 10:301-312
31. Cohen DM, Ben-Amitai D, Feinmesser M, Zvulunov A (2009) Childhood lichen planus pemphigoides: a case report and review of the literature. Pediatr Dermatol 26:569-574
32. Coleman MD, Scott AK, Breckenridge AM, Park BK (1990) The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol 30:761-767
33. Coleman MD, Rhodes LE, Scott AK, Verbov JL, Friedmann PS, Breckenridge AM, Park BK (1992) The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol 34:244-249
34. Coleman MD, Russell RM, Tingle MD, Park BK (1992) Inhibition of dapsone-induced methaemoglobinaemia by cimitidine in the presence of trimethoprim in the rat. J Pharm Pharmacol 44:114-118
35. Coleman MD (1993) Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 129:507-513
36. Coleman MD, Jacobus DP (1993) Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro - II. Movement of dapsone across a semipermeable membrane into erythrocytes and plasma. Biochem Pharmacol 46:1363-1368
37. Coleman MD, Jacobus DP (1993) Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocythes in vitro. Biochem Pharmacol 45:1027-1033
38. Coleman MD (1995) Dapsone toxicity: some current perspectives. Gen Pharmacol 26:1461-1467
39. Collier PM, Kelly SE, Wojnarowska F (1994) Linear IgA disease and pregnancy. J Am Acad Dermatol 30:407-411
40. Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A (2005) Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults - a report on 90 patients. Eur J Haematol 75:328-331
41. Dapsone (2011) In: McEvoy GK (ed) AHFS drug information. American Society of Health-System Pharmacists, Bethesda (MD), pp 622-626
42. Dayani A, Gould DJ, Cambell S (1992) Delayed pressure urticaria: treatment with dapsone. J Dermatolog Treat 3:61-62
43. Debol SM, Herron MJ, Nelson RD (1997) Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoatractant-induced signal transduction. J Leukoc Biol 62:827-836
44. DeForge LE, Fantone JC, Kenney JS, Remick DG (1992) Oxygen radical scavengers selectively inhibits interleukin 8 production in human whole blood. J Clin Invest 90:2123-2129
45. DeLeo VA, Scheide S, Horlich H, Southern W, Harber LC, Weinstein IB (1986) The effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on phospholipid metabolism of human epidermal keratinocytes in culture. Carcinogenesis 7:937-942
46. Diaz-Ruiz A, Zavala C, Montes S, Ortiz-Plata A, Salgado-Ceballos H, Orozco-Suarez S, Nava-Ruiz C, Pérez-Neri I, Pérez-Severiano F, Rios C (2008) Antioxidant, anti-inflammatory and antiapoptotic effects of dapsone in a model of brain ischemia/reperfusion in rats. J Neurosci Res 86:3410-3419
47. Doull JA (1963) Sulfone therapy of leprosy. Background, early history and present status. Int J Lepr 31:143-160
48. Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, Garrett S (2007) Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 56:439e1-439e10
49. Drayer DE, Strong JM, Jones B, Sandler A, Reidenbeg MM (1974) In vitro acetylation of drugs by human blood cells. Drug Metab Dispos 2:499-505
50. Duncan ME, Pearson JM, Rees RJ (1981) The association of pregnancy and leprosy. II. Pregnancy in dapsone-resistant leprosy. Lepr Rev 52:263-270
51. Durand JM, Lefevre P, Hovette P, Issifi S, Mongin M (1991) Dapsone for thrombocytopenic purpura related to human immunodeficiency virus infection. Am J Med 90:675-677
52. Durand JM, Lefèvre P, Hovette P, Mongin M, Soubeyrand J (1991) Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients. Br J Haematol 78:459-460
53. Engin B, Ozdemir M (2008) Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 22:481-486
54. Esca SA, Pehamberger H, Silny W, Holubar K (1981) Polymorphonuclear leukocyte chemotaxis in dermatitis herpetiformis. Acta Derm Venereol 61:61-63
55. Esterly NB, Furey NL, Flanagan LE (1978) The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 70:51-55
56. Esteves J, Brãndao F (1950) Acerca da açcão das sulfamidas e das sulfonas na doença de Duhring. Trab Soc Port Dermatol Venereol 8:209-217
57. Faget GH, Pogge RC, Johansen FA, Dinan JF, Prejean BM, Eccles CG (1943) The promin treatment of leprosy. Public Health Rep 58:1729-1741
58. Fonacier L, Aquino M, Kim B (2010) Clinical evaluation and treatment of chronic urticaria. Postgrad Med 122:148-156
59. Fourneau E, Trèfouel J, Nitti F, Bovet D, Tréfouel J (1937) Action anti-streptococcique des dérivés sulfurés organiques. C R Acad Sci 204:1763-1766
60. Fräki JE, Hopsu-Havu VK (1977) Inhibition of human skin proteinases by chloroquine, dapsone and sulfapyridine. Arch Dermatol Res 259:113-115
61. Frayling IM, Addison GM, Chattergee K, Meakin G (1990) Methaemoglobinaemia in children treated with prilocaine-lignocaine cream. BMJ 301:153-154
62. Fredenberg MF, Malkinson FD (1987) Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 16:772-778
63. Fromm E, Wittmann J (1908) Derivate des p-nitrothiophenols. Ber Dtsch Chem Ges 41:2264-2273
64. Gemmell DK, Cottney J, Lewis AJ (1979) Comparative effects of drugs on four paw oedema models in the rat. Agents Actions 9:107-116
65. Grabbe J, Haas N, Möller A, Henz BM (2000) Erythema elevatum diutinum - evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol 143:415-420
66. Grundmann SA, Kiefer S, Luger TA, Brehler R (2011) Delayed pressure urticaria - dapsone heading for first-line therapy? J Dtsch Dermatol Ges 9:908-912
67. Grunwald MH, Amichai B (1996) Dapsone - the treatment of infectious and inflammatory diseases in dermatology. Int J Antimicrob Agents 7:187-192
68. Gürcan HM, Ahmed AR (2009) Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 10:383-396
69. Haar D, Sølvkjaer M, Unger B, Rasmussen KJ, Christensen L, Hansen TM (1993) A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis. Scand J Rheumatol 22:113-118
70. Hamada K, Hiyoshi T, Kobayashi S, Ishida S, Yagi K, Seino M (1991) Anticonvulsive effect of dapsone (4,4′-diaminodiphenyl sulfone) on amygdala-kindled seizures in rats and cats. Epilepsy Res 10:93-102
71. Hargrave D (2009) Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg 23:351-363
72. Harvath L, Yancey K, Katz S (1986) I. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol 137:1305-1311
73. Hashimoto K, Singer K, Lazarus GS (1984) The effect of corticosteroids, dapsone and gold upon plasminogen activator synthesis and secretion by human epidermal cells cultured with pemphigus antibody. Br J Dermatol 110:293-297
74. Hegarty AM, Ormond M, Sweeney M, Hodgson T (2010) Dapsone efficacy and adverse events in the management of mucous membrane pemphigoid. Eur J Dermatol 20:223-224
75. Henz BM, Zuberbier T, Grabbe J, Monroe E (eds) (1998) Urticarias. Clinical, diagnostic and therapeutic aspects. Springer, Berlin
76. Hocking DR (1968) Neonatal haemolytic disease due to dapsone. Med J Aust 1:1130-1131
77. Homeida M, Babikr A, Daneshmend TK (1980) Dapsone-induced optic atrophy and motor neuropathy. Br Med J 281:1180
78. Ishida S, Hamada K, Yagi K, Seino M (1992) Comparing the anticonvulsive effects of dapsone on amygdala-kindled seizures and hippocampal-kindled seizures in rats. Acta Neurol Scand 85:132-135
79. Israili ZH, Cucinell SA, Vaught J, Davis E, Lesser JM, Dayton PG (1973) Studies of the metabolism of dapsone in man and experimental animals: formation of N-hydroxy metabolites. J Pharmacol Exp Ther 187:138-151
80. Kanoh S, Tanabe T, Rubin BK (2011) Dapsone inhibits IL-8 secretion from human bronchial epithelial cells stimulated with lipopolysaccharide and resolves airway inflammation in the ferret. Chest 140:980-990
81. Kar BR (2008) Dapsone-induced photosensitivity: a rare clinical presentation. Photodermatol Photoimmunol Photomed 24:270-271
82. Kardos M, Levine D, Gurcan HM, Ahmed RA (2009) Pemphigus vulgaris in pregnancy: analysis of current data on the management and outcomes. Obstet Gynecol Surv 64:739-749
83. Kasperkiewicz M, Zillikens D (2007) The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 33:67-77
84. Kasperkiewicz M, Schmidt E (2009) Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 6:270-280
85. Kast RE, Scheuerle A, Wirtz CR, Karpel-Massler G, Halatsch ME (2011) The rationale of targeting neutrophils with dapsone during glioblastoma treatment. Anticancer Agents Med Chem 11:756-761
86. Kast RE, Lefrance F, Karpel-Massler G, Halatsch ME (2012) Why dapsone stops seizures and may stop neutrophils' delivery of VEGF to glioblastoma. Br J Neurosurg 26:813-817
87. Katz SI, Hertz KC, Crawford PS, Gazze LA, Frank MM, Lawley TJ (1976) Effect of sulfones on complement deposition in dermatitis herpetiformis and on complement-mediated guinea-pig reactions. J Invest Dermatol 67:688-690
88. Kazmierowski JA, Ross JE, Peizner DS, Wuepper KD (1984) Dermatitis herpetiformis: effects of sulfones and sulfonamides on neutrophil myeloperoxidase-mediated iodination and cytotoxicity. J Clin Immunol 4:55-64
89. Kelly JW, Scott J, Sandland M, Van der Weyden MB, Marks R (1984) Vitamin E and dapsone-induced hemolysis. Arch Dermatol 120:1582-1584
90. Kelso JM, Bai CL, Ahokas JT, Wright PF (1997) In vitro effects of MOCA and dapsone on rat hepatic and splenic immune cells. Immunopharmacology 35:183-193
91. Kenner DJ, Holt K, Agnello R, Chester GH (1980) Permanent retinal damage following massive dapsone overdose. Br J Ophthalmol 64:741-744
92. Kettle AJ, Winterbourn CC (1991) Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol 41:1485-1492
93. Kettle AJ, Gedye CA, Winterbourn CC (1993) Superoxide is an antagonist of anitinflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase. Biochem Pharmacol 45:2003-2010
94. Khan G (1985) Dapsone is safe during pregnancy. J Am Acad Dermatol 13:838-839
95. Khan FD, Roychowdhury S, Nemes R, Vyas PM, Woster PM, Svensson CK (2006) Effect of pro-inflammatory cytokines on the toxicity of the arylhydroxylamine metabolites of sulphamethoxazole and dapsone in normal human keratinocytes. Toxicology 218:90-99
96. Kim SM, Kim DS, Jeong CH, Kim DH, Kim JH, Jeon HB, Kwon SJ, Jeun SS, Yang YS, Oh W, Chang JW (2011) CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas. Biochem Biophys Res Commun 407:741-746
97. King JA, Marks RA (1958) Pregnancy and leprosy; a review of 52 pregnancies in 26 patients with leprosy. Am J Obstet Gynecol 76:438-442
98. Knudson RM, Kalaaji AN, Bruce AJ (2010) The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther 23:268-280
99. Kumar B, Ganguly NK, Kaur S, Vaishnavi C, Chakravarti RN (1983) Effect of dapsone (DDS) on T-cells and their response to PHA and lepromin in tuberculoid leprosy patients. Lepr India 55:465-471
100. Lammers AM, van de Kerkhof PC, Schalwijk J, Mier PD (1986) Elastase, a marker for neutrophils in skin infiltrates. Br J Dermatol 115:181-186
101. Lang PG Jr (1979) Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1:479-492
102. Lewis AJ, Gemmell DK, Stimson WH (1978) The anti-inflammatory profile of dapsone in animal models of inflammation. Agents Actions 8:578-586
103. Lopez-Gomez M, Corona T, Diaz-Ruiz A, Rios C (2011) Safety and tolerability of dapsone for the treatment of patients with drug-resistant, partial-onset seizures: an open-label trial. Neurol Sci 32:1063-1067
104. Lorenz M, Wozel G, Schmitt J (2012) Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 92:194-199
105. Lowe J (1952) Studies in sulphone therapy. Lepr Rev 23:4-29
106. Lush R, Iland H, Peat B, Young G (2000) Successful use of dapsone in refractory pregnancy-associated idiopathic thrombocytopenic purpura. Aust N Z J Med 30:105-107
107. Maloff BL, Fox D, Bruin E, Di Meo TM (1988) Dapsone inhibits LTB4 binding and bioresponse at the cellular and physiologic levels. Eur J Pharmacol 158:85-89
108. Maurer M, Altrichter S, Ardelean E, Krause K, Magerl M, Metz M, Siebenhaar F, Weller K, Zuberbier T (2010) Therapeutic alternatives for antihistamine-refractory urticaria. Hautarzt 61:765-769
109. Maurus JN (1978) Hansen's disease in pregnancy. Obstet Gynecol 52:22-25
110. Millar BW, Macdonald KJ, Macleod TM, Raffle EJ (1984) Dapsone and human polymorphonuclear leucocyte chemotaxis in dermatitis herpetiformis. Acta Derm Venereol 64:433-436
111. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT (1995) Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 58:556-566
112. Miyachi Y, Niwa Y (1982) Effects of potassium iodide, colchicine and dapsone on the generation by normal polymorphonuclear leukocyte-derived oxygen intermediates. Br J Dermatol 107:209-214
113. Miyachi Y, Yanase K, Imamura S, Niwa Y (1982) Increased hydroxyl radical generation by normal polymorphonuclear leukocytes incubated in sera from patients with leukocytoclastic vasculitis. Arch Dermatol Res 274:65-71
114. Miyachi Y, Niwa Y (1983) Effects of psoriatic sera on the generation of oxygen intermediates by normal polymorphonuclear leucocytes. Arch Dermatol Res 275:23-26
115. Miyachi Y, Yoshioka A, Horio T, Imamura S, Niwa Y (1986) Prurigo pigmentosa: a possible mechanism of action of sulfonamides. Dermatologica 172:82-88
116. Modschiedler K, Weller M, Wörl P, von den Driesch P (2000) Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. Arch Dermatol Res 292:32-36
117. Mukaida N (2000) Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 72:391-398
118. Nader-Kawachi J, Gongora-Rivera F, Santos-Zambrano J, Calzada P, Rios C (2007) Neuroprotective effect of dapsone in patients with acute ischemic stroke: a pilot study. Neurol Res 29:331-334
119. Nagata Y, Koshaka K, Ito T (1985) Negative observations on immunological side effects of rifampin and dapsone in mice. Int J Lepr Other Mycobact Dis 53:421-427
120. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P (2011) Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol 38:243-253
121. Niwa Y, Sakane T, Miyachi Y (1984) Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediates - in comparison with that of colchicine and various scavengers. Biochem Pharmacol 33:2355-2360
122. Niwa Y, Miyachi Y (1985) Inhibitor effects of dapsone on enzymatic acitivities of membrane phospholipids in human blood cells. Arch Dermatol Res 277:473-477
123. Palazzoli M, Bovet D (1937) Action de la di(paracetylaminophenyl)sulfone (1399F) dans les urétrites gonococciques aiguës et chroniques. Bull Soc Fr Dermatol Syphiligr 44:1900
124. Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S, Nicoll-Griffith DA, Obach RS, Routledge P, Smith DA, Tweedie DJ, Vermeulen N, Williams DP, Wilson ID, Baillie TA (2011) Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 10:292-306
125. Pfeiffer G, Wozel G (2003) Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 48:308-309
126. Piette EW, Werth VP (2011) Dapsone in the management of autoimmune bullous diseases. Dermatol Clin 29:561-564
127. Prussick R, Ali MA, Rosenthal D, Guyatt G (1992) The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 128:210-213
128. Rhodes LE, Tingle MD, Park BK, Chu P, Verbov JL, Friedmann PS (1995) Cimetidine improves the therapeutic/toxic ratio of dapsone patients on chronic dapsone therapy. Br J Dermatol 132:257-262
129. Rios C, Nader-Kawachi J, Rodriguez-Payán AJ, Nava-Ruiz C (2004) Neuroprotective effect of dapsone in an occlusive model of focal ischemia in rats. Brain Res 999:212-215
130. Rodríguez E, Méndez-Armenta M, Villeda-Hernández J, Galván-Arzate S, Barroso-Moguel R, Rodríguez F, Rios C, Santamaria A (1999) Dapsone prevents morphological lesions and lipid peroxidation induced by quinolinic acid in rat corpus striatum. Toxicology 139:111-118
131. Ruzicka T, Bauer A, Glück S, Born M (1981) Effects of dapsone on passive Arthus reaction and chemotaxis and phagocytosis of polymorphonuclear leukocytes. Arch Dermatol Res 270:347-351
132. Ruzicka T, Goerz G (1981) Systemic lupus erythematosus and vasculitic urticaria. Effect of dapsone and complement levels. Dermatologica 162:203-205
133. Ruzicka T, Goerz G (1981) Dapsone in the treatment of lupus erythematosus. Br J Dermatol 104:53-56
134. Ruzicka T, Wasserman SI, Soter NA, Printz MP (1983) Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapsone. J Allergy Clin Immunol 72:365-370
135. Salomon K (2000) Humane In-vivo-Untersuchungen zur antientzündlichen Wirksamkeit von Diaminodiphenylsulfon (Dapson). (Thesis). Technical University, University Hospital, Department of Dermatology, Dresden
136. Samsoen M, Bousquet F, Basset A (1981) Sulfones. Indications excluding infectious diseases. Ann Dermatol Venereol 108:911-920
137. Sanders SW, Zone JJ, Foltz RL, Tolman KG, Rollins DE (1982) Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med 96:465-466
138. Santamaria A, Ordaz-Moreno J, Rubio-Osornio M, Solís- Hernández F, Rios C (1997) Neuroprotective effect of dapsone against quinolinate- and kainate-induced striatal neurotoxicities in rats. Pharmacol Toxicol 81:271-275
139. Schmidt E, Reimer S, Kruse N, Brocker EB, Zillikens D (2001) The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 124:157-162
140. Sengupta U, Ghei SK, Venkatesan K, Bharadwaj VP (1979) In vivo effect of DDS on phytohemagglutinin (PHA)-induced lymphocyte transformation cultures in normal healthy volunteers. Int J Lepr Other Mycobact Dis 47:167-170
141. Shibata K, Tateishi T, Yamasaki R, Ohyagi Y, Kira J (2010) Successful treatment of a case of steroid-dependent neuro-Sweet disease with dapsone. Rinsho Shinkeigaku 50:257-261
142. Smith LC, Cox NH (2008) Dapsone treatment for eosinophilic fasciitis. Arch Dermatol 144:845-847
143. Sneddon IB, Wilkinson DS (1956) Subcorneal pustular dermatosis. Br J Dermatol 68:385-394
144. Stendahl O, Molin L, Dahlgren C (1978) The inhibition of polymorphonuclear leukocyte by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest 62:214-220
145. Stöckel S, Meurer M, Wozel G (2001) Dapsone-induced photodermatitis in a patient with linear IgA dermatosis. Eur J Dermatol 11:50-53
146. Stratton LP, Rudolph AS, Knoll WK Jr, Bayne S, Farmer MC (1988) The reduction of methemoglobin levels by antioxidants. Hemoglobin 12:353-368
147. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, Bilker WB, Pettitt D (2003) Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 349:1628-1635
148. Suda T, Suzuki Y, Matsui T, Inoue T, Niide O, Yoshimaru T, Suzuki H, Ra C, Ochiai T (2005) Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner. Br J Dermatol 152:887-895
149. Theron A, Anderson R (1985) Investigation of the protective effects of the antioxidants ascorbate, cysteine, and dapsone on the phagocyte-mediated oxidative inactivation of human alpha-1-protease inhibitor in vitro. Am Rev Respir Dis 132:1049-1054
150. Thompson DM, Souhami R (1975) Suppression of the arthus reaction in the guinea-pig by dapsone. Proc R Soc Med 68:273
151. Thuong-Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ (1993) Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol 100:349-355
152. Tingle MD, Mahmud R, Maggs JL, Pirmohamed M, Park BK (1997) Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. J Pharmacol Exp Ther 283:817-823
153. Tirado-Sanchez A, Diaz-Molina V, Ponce-Olivera RM (2012) Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid. Allergol Immunopathol (Madr) 40:152-155
154. Tuffanelli DL (1982) Successful pregnancy in a patient with dermatitis herpetiformis treated with low-dose dapsone. Arch Dermatol 118:876
155. Uehleke H, Taberelli S (1973) N-hydroxylation of 4,4′- diaminodiphenylsulphone (Dapsone) by liver microsomes, and in dogs and humans. Naunyn Schmiedebergs Arch Pharmacol 278:55-68
156. Uetrecht J, Zahid N, Shear NH, Biggar WD (1988) Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 245:274-279
157. van Zyl JM, Basson K, Kriegler A, van der Walt BJ (1991) Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. A possible correlation with their anti-inflammatory properties. Biochem Pharmacol 42:599-608
158. Varghese L, Viswabandya A, Mathew AJ (2008) Dapsone, danazol, and intrapartum splenectomy in refractory ITP complicating pregnancy. Indian J Med Sci 62:452-455
159. Veggi LM, Pretto L, Ochoa EJ, Catania VA, Luquita MG, Taborda DR, Sánchez Pozzi EJ, Ikushiro S, Coleman MD, Roma MG, Mottino AD (2008) Dapsone induces oxidative stress and impairs antioxidant defenses in rat liver. Life Sci 83:155-163
160. Walker JG, Kadia T, Brown L, Juneja HD, de Groot JF (2009) Dapsone induced methemoglobinemia in a patient with glioblastoma. J Neurooncol 94:149-152
161. Webster GF, Alexander JC, McArthur WP, Leyden JJ (1984) Inhibition of chemiluminescence in human neutrophils by dapsone. Br J Dermatol 110:657-663
162. Webster GF (2010) Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol 9:532-536
163. Weiss SJ (1989) Tissue destruction by neutrophils. N Engl J Med 320:365-376
164. Wolf R, Tüzün B, Tüzün Y (2000) Dapsone: unapproved uses or indications. Clin Dermatol 18:37-53
165. Wozel G (1996) Dapson - Pharmakologie. Wirkmechanismus und klinischer Einsatz, Thieme, Stuttgart
166. Wozel G, Blümlein K, Blasum C, Lehmann B, Winter C (1999) Comments on:"Preventive effect of dapsone on renal scarring following mannose-sensitive piliated bacterial infection" by Mochida et al. (Chemotherapy 1998; 44:36-41). Chemotherapy 45:233-235
167. Wozel G, Thiele B (1987) Urticaria vasculitis and sulfone, a case report. Z Hautkr 62:407-409
168. Wozel G, Köstler E, Barth J (1988) Results of therapy studies with anti-inflammatory substances in occlusive conditions in psoriasis. Dermatol Monatsschr 174:421-423
169. Wozel G, Barth J (1988) Current aspects of modes of action of dapsone. Int J Dermatol 27:547-552
170. Wozel G (1989) The story of sulfones in tropical medicine and dermatology. Int J Dermatol 28:17-21
171. Wozel G, Lehmann B (1995) Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol 8:196-202
172. Wozel G, Blasum C, Winter C, Gerlach B (1997) Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study. Inflamm Res 46:420-422
173. Wozel G (2010) Innovative use of dapsone. Dermatol Clin 28:599-610
174. Xia M, Qin S, McNamara M, Mackay C, Hyman BT (1997) Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer's disease. Am J Pathol 150:1267-1274
175. Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GB (2011) Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology 222:342-346
176. Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R (2012) Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol 87:321-323
177. Zhu KJ, He FT, Jin N, Lou JX, Cheng H (2009) Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome. J Clin Pharm Ther 34:489-492
178. Zhu YI, Stiller MJ (2001) Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45:420-434
179. Zone JJ, Meyer LJ (1989) Dermatitis herpetiformis. Immunol Ser 46:565-582
180. Zubebier T, Aberer W, Brockow K, Grabbe J, Hamelmann E, Hartmann K, Jakob T, Maurer M, Merk HF, Ollert M, Ruëff F, Schmid-Grendelmeier P, Staubach P, Voigtmann I, Wedi B (2011) Teil 2: therapie der Urtikaria - deutschsprachige Version der internationalen S3-Leitlinie. Allergo J 20:259-276
181. Zuidema J, Hilbers-Modderman ES, Merkus FW (1986) Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 11:299-315